Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.
Saved in:
| Title: | Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial. |
|---|---|
| Authors: | Lorusso D; Department of Biomedical Science, Humanitas University, Pieve Emanuele, Italy; Humanitas San Pio X Hospital, Milan, Italy. Electronic address: domenica.lorusso@hunimed.eu., Gladieff L; Oncopole Claudius Regaud IUCT-Oncopole, Toulouse, France; GINECO, Paris, France., O'Malley DM; James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA., Kim JW; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, South Korea., Garbaos G; Instituto Médico de la Fundación Estudios Clínicos, Santa Fe, Argentina., Fagotti A; Gynecologic Oncology Unit, Fondazione Policlinico Universitario A Gemelli, IRCCS, Rome, Italy., Gilbert L; Division of Gynecologic Oncology, Research Institute, McGill University Health Centre, Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada., Mileshkin L; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Quesada S; GINECO, Paris, France; Montpellier Cancer Institute, Montpellier, France., Hopp E; Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI, USA., Lee YJ; Yonsei University College of Medicine, Seoul, South Korea., Oaknin A; Medical Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain., Scaranti M; Rede Américas Oncologia, Hospital 9 de Julho, São Paulo, Brazil., Kim BG; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Clamp A; The Christie NHS Foundation Trust, Manchester, UK; University of Manchester, Manchester, UK., Prillaman C; Virginia Oncology Associates, Norfolk, VA, USA., Diakos C; Royal North Shore Hospital, St Leonards, NSW, Australia., Bagaméri A; Department of Gynecology, Hungarian National Institute of Oncology, Budapest, Hungary., Leiser AL; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Salutari V; Department of Woman, Child, and Public Health, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy., Monk BJ; Florida Cancer Specialists and Research Institute, West Palm Beach, FL, USA., Follana P; GINECO, Paris, France; Centre Antoine Lacassagne, Nice, France., McClung E; Stanford University, Palo Alto, CA, USA., Carbone V; Gynecologic Oncology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy., Slomovitz B; Mount Sinai Comprehensive Cancer Center, Miami Beach, FL, USA., Giudice E; Humanitas San Pio X Hospital, Milan, Italy., Cannizzaro MC; Department of Women and Children's Health Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy., Gavoille L; Gentilly Oncology Center, Interregional Institute of Oncology, Nancy, France., Devaux A; Oncology Department of Grand Hôpital de Charleroi, Charleroi, Belgium; Belgium and Luxembourg Gynaecological Oncology Group, Leuven, Belgium., Scollo P; Department of Medicine and Surgery, Kore University of Enna, Enna, Italy., Scandurra G; Dipartimento di Medicina, Kore University of Enna, Enna, Italy; Medical Oncology Unit, Cannizzaro Hospital, Catania, Italy., Cassani C; Department of Clinical, Surgical, Diagnostic, and Pediatric Sciences, University of Pavia, Pavia, Italy; Unit of Obstetrics and Gynecology, IRCCS San Matteo Foundation, Pavia, Italy., Artioli G; Azienda ULSS2 Marca Trevigiana, Treviso, Italy., Van Gorp T; Belgium and Luxembourg Gynaecological Oncology Group, Leuven, Belgium; University Hospital Leuven, Leuven Cancer Institute, Leuven, Belgium., Santaballa A; Department of Medical Oncology, La Fe University Hospital, IIS La Fe, Valencia, Spain., Dreiling LK; Corcept Therapeutics, Redwood City, CA, USA., Kesner-Hays A; Corcept Therapeutics, Redwood City, CA, USA., Tudor IC; Corcept Therapeutics, Redwood City, CA, USA., Jubb AM; Corcept Therapeutics, Redwood City, CA, USA., Colombo N; Gynecologic Oncology Program, European Institute of Oncology, IRCCS, Milan, Italy., Olawaiye AB; University of Pittsburgh School of Medicine and UPMC Magee-Women's Hospital, Gynecologic Oncology Group, Pittsburgh, PA, USA. |
| Source: | Lancet (London, England) [Lancet] 2026 Apr 18; Vol. 407 (10538), pp. 1513-1524. Date of Electronic Publication: 2026 Apr 10. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
